Literature DB >> 26960332

Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design.

Hampig Raphael Kourie1,2, Fouad Aoun3,4.   

Abstract

New concepts of trial design are being developed based on biomarkers, namely basket and umbrella trials. Basket trials appear optimally positioned to evaluate new molecular markers for testicular germ cell tumors, a rare heterogeneous disease with relatively few molecular alterations. However, not uncommonly, the "balls" fall outside the "basket". In this short communication, we discussed the different causes limiting the inclusion of TGCT in basket trials and we proposed a new design for trials suitable for this malignancy.

Entities:  

Keywords:  Basket trial; Design; Testicular germ cell tumors; Trial

Mesh：

Substances：

Year:  2016        PMID： 26960332     DOI： 10.1007/s10637-016-0338-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  9 in total

1.  Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.

Authors:  Roelof Koster; Alessandra di Pietro; Hetty Timmer-Bosscha; Johan H Gibcus; Anke van den Berg; Albert J Suurmeijer; Rainer Bischoff; Jourik A Gietema; Steven de Jong
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

2.  MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death.

Authors:  Lin Liu; Jie Lian; Huijuan Zhang; Hui Tian; Meng Liang; Mianmian Yin; Fei Sun
Journal:  J Cell Physiol       Date:  2013-12       Impact factor: 6.384

Review 3.  Cisplatin resistance in germ cell tumours: models and mechanisms.

Authors:  C Jacobsen; F Honecker
Journal:  Andrology       Date:  2014-12-29       Impact factor: 3.842

4.  microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells.

Authors:  Helong Huang; Hui Tian; Zhengzheng Duan; Yunxia Cao; Xian-Sheng Zhang; Fei Sun
Journal:  Cell Signal       Date:  2014-01-22       Impact factor: 4.315

Review 5.  Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.

Authors:  Francesca Cavallo; Darren R Feldman; Marco Barchi
Journal:  Int J Dev Biol       Date:  2013       Impact factor: 2.203

6.  MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours.

Authors:  K-P Dieckmann; M Spiekermann; T Balks; I Flor; T Löning; J Bullerdiek; G Belge
Journal:  Br J Cancer       Date:  2012-10-11       Impact factor: 7.640

7.  Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.

Authors:  R Koster; H Timmer-Bosscha; R Bischoff; J A Gietema; S de Jong
Journal:  Cell Death Dis       Date:  2011-04-21       Impact factor: 8.469

Review 8.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

9.  Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle.

Authors:  Ad J M Gillis; Martin A Rijlaarsdam; Ronak Eini; Lambert C J Dorssers; Katharina Biermann; Matthew J Murray; James C Nicholson; Nicholas Coleman; Klaus-Peter Dieckmann; Gazanfer Belge; Jörn Bullerdiek; Tom Xu; Nathalie Bernard; Leendert H J Looijenga
Journal:  Mol Oncol       Date:  2013-08-20       Impact factor: 6.603
  9 in total
  1 in total

1.  Reporting of master protocols towards a standardized approach: A systematic review.

Authors:  Ellie G Siden; Jay Jh Park; Michael J Zoratti; Louis Dron; Ofir Harari; Kristian Thorlund; Edward J Mills
Journal:  Contemp Clin Trials Commun       Date:  2019-07-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.